Investors

Bioasis Technologies, Inc. is a science-driven company focused on revolutionizing science by transporting therapeutic payloads across the blood-brain barrier and into the brain. Our goal is to generate shareholder value by developing and commercializing our proprietary brain delivery technology, xB3, to make life-saving drugs brain-penetrant and deliver those drugs at a therapeutically relevant dose.

BTI.V
loading
loading
loading
Today's Open:
loading
Previous Close:
loading
High:
loading
Low:
loading
Volume:
loading

All Public Filings (Canada)

Most Recent Financial Reports (US)

Corporate Presentation

Investor News and Events

  • Jun. 29, 2020 Bioasis Announces Filing of Its Fourth Quarter and Fiscal Year-End Financial Statements and MD&A

    GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc. (TSXV:BTI.V; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases,… Read more »

  • Jun. 24, 2020 Bioasis Announces Conversion of Debenture Interest Into Equity

    GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc. (TSXV:BTI.V; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases,… Read more »

  • Jun. 17, 2020 Bioasis Announces Analyst Coverage Initiated by Edison Group

    GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSXV:BTI), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases,… Read more »

All Events and Presentations